Tenaya Therapeutics, Inc. (TNYA)
$0.52-8.77%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $87M
- Beta
- 2.88
- P/E (TTM)
- -0.74
- Short % float
- 14.67%
- Days to cover
- 7.5
- SI change
- +5.9%
- 1W
- -5.45%
- 1M
- -24.64%
- vs SPY 1W
- -5.32%
- vs SPY 1M
- -27.14%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 18
- GROWTH
- 19
- GARP
- 5
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-64.8%
REV YoY-
ROE-108.0%
EPS YoY-
ROA-110.2%
GROSS264
OP-7930
NET-7724
[VALUATION]
P/E TTM-0.74
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.22
P/FCF-
EV/EBITDA-0.11
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E5.69
ALTMAN Z-
CURR RATIO4.52
ND/EBITDA-
BETA2.88
Company news
FAQ
- What is LOPJLB’s current signal on TNYA?
- LOPJLB’s latest quantitative signal on Tenaya Therapeutics, Inc. (TNYA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TNYA in?
- Tenaya Therapeutics, Inc. (TNYA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Tenaya Therapeutics, Inc. (TNYA) do?
- Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventric…